Until recently, Kaposi's sarcoma was considered a rare neoplasm in the United States. In the past two years, a strikingly increased incidence was observed, primarily in young homosexual males with acquired immunodeficiency syndromes (AIDS) and to a lesser degree in renal transplant recipients. A feature common to both these situations is the frequency of active cytomegalovirus (CMV) infection. Epidemiologic studies suggest an association between CMV and Kaposi's sarcoma in other populations as well. Two ways in which CMV may predispose to Kaposi's sarcoma are by direct transformation of appropriate target cells or by indirect suppressive effects on immunoregulatory control mechanisms. We will explore both of these possibilities by studying high risk subjects for CMV infections and immunological defects, and by attempting in vitro transformation of potential target cells with CMV isolates from such individuals. In addition, we will study the possible interaction of CMV and chemicals such as nitrites in target cell transformation. Although CMV has been the virus most closely associated with AIDS and Kaposi's sarcoma, other viruses may also be involved in these syndromes. Epstein-Barr virus (EBV) and the newly described human T cell leukemia virus (HTLV) are possible offenders. We will evaluate high risk patients sequentially for infection with these agents and attempt to assess their importance in the pathogenesis of subsequent syndromes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA035020-03
Application #
3548358
Study Section
(SSS)
Project Start
1983-05-01
Project End
1986-04-30
Budget Start
1985-05-01
Budget End
1986-04-30
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
Margalith, M; D'Aquila, R T; Manion, D J et al. (1995) HIV-1 DNA in fibroblast cultures infected with urine from HIV-seropositive cytomegalovirus (CMV) excretors. Arch Virol 140:927-35
Schooley, R T (1995) HIV-1-specific cytotoxic T-cell responses. AIDS 9 Suppl A:S113-6
Rusconi, S; Merrill, D P; Hirsch, M S (1994) Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J Infect Dis 170:1361-6
Mazzulli, T; Rusconi, S; Merrill, D P et al. (1994) Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother 38:656-61
Mazzulli, T; Rubin, R H; Ferraro, M J et al. (1993) Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS. J Clin Microbiol 31:2824-7
Margalith, M; Medina, D J; Hsiung, G D et al. (1993) Interactions between HIV-1 and cytomegalovirus in human osteosarcoma cells carrying both viruses. AIDS Res Hum Retroviruses 9:519-27
Conway, B; Bechtel, L J; Adler, K A et al. (1992) Comparison of spot-blot and microtitre plate methods for the detection of HIV-1 PCR products. Mol Cell Probes 6:245-9
Johnson, V A; Merrill, D P; Chou, T C et al. (1992) Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 166:1143-6
Eron Jr, J J; Johnson, V A; Merrill, D P et al. (1992) Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother 36:1559-62
Johnson, V A; Merrill, D P; Videler, J A et al. (1991) Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 164:646-55

Showing the most recent 10 out of 47 publications